The Department of Veterans Affairs is launching a nationwide clinical trial to test whether semaglutide can help treat alcohol use disorder in veterans. The department said more than 400,000 veterans nationwide have been diagnosed with the condition.
Semaglutide is sold as Ozempic for Type 2 diabetes and Wegovy for chronic weight management. The Food and Drug Administration has approved it for those uses, but not for alcohol use disorder.
The Department of Veterans Affairs said researchers will study whether the GLP-1 receptor agonist affects parts of the brain involved in reward and could offer another treatment option for veterans with moderate or severe alcohol use disorder if it is shown to be safe and effective.
The study, called the Cessation or Reduction of Alcohol Consumption in Veterans, or CRAVE, trial, will enroll more than 600 veterans ages 18 to 80 at 18 Department of Veterans Affairs medical centers nationwide. Participants will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety evaluation. Researchers will track changes in alcohol consumption, overall health, and quality of life.
The department said veterans should not self-medicate or replace evidence-based treatment for alcohol use disorder with GLP-1 medications without first consulting a health care provider.
The Department of Veterans Affairs cited a March analysis that found patients taking GLP-1 medications had lower rates of alcohol use disorder and other substance use disorders than similar patients taking other diabetes medications. It also said larger, controlled clinical trials are needed to determine whether semaglutide is safe and effective for treating alcohol use disorder.